131 related articles for article (PubMed ID: 27080012)
1. GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellström-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Möröy T; Dührsen U; Maciejewski J; Khandanpour C
Exp Hematol; 2016 Jul; 44(7):590-595.e1. PubMed ID: 27080012
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
3. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
4. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C; Thiede C; Valk PJ; Sharif-Askari E; Nückel H; Lohmann D; Horsthemke B; Siffert W; Neubauer A; Grzeschik KH; Bloomfield CD; Marcucci G; Maharry K; Slovak ML; van der Reijden BA; Jansen JH; Schackert HK; Afshar K; Schnittger S; Peeters JK; Kroschinsky F; Ehninger G; Lowenberg B; Dührsen U; Möröy T
Blood; 2010 Mar; 115(12):2462-72. PubMed ID: 20075157
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
Khandanpour C; Eisfeld C; Nimmagadda SC; Raab MS; Weinhold N; Seckinger A; Hose D; Jauch A; Försti A; Hemminki K; Hielscher T; Hummel M; Lenz G; Goldschmidt H; Huhn S
Front Oncol; 2021; 11():757664. PubMed ID: 34760702
[TBL] [Abstract][Full Text] [Related]
6. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Frank D; Patnana PK; Vorwerk J; Mao L; Gopal LM; Jung N; Hennig T; Ruhnke L; Frenz JM; Kuppusamy M; Autry R; Wei L; Sun K; Mohammed Ahmed HM; Künstner A; Busch H; Müller H; Hutter S; Hoermann G; Liu L; Xie X; Al-Matary Y; Nimmagadda SC; Cano FC; Heuser M; Thol F; Göhring G; Steinemann D; Thomale J; Leitner T; Fischer A; Rad R; Röllig C; Altmann H; Kunadt D; Berdel WE; Hüve J; Neumann F; Klingauf J; Calderon V; Opalka B; Dührsen U; Rosenbauer F; Dugas M; Varghese J; Reinhardt HC; von Bubnoff N; Möröy T; Lenz G; Batcha AMN; Giorgi M; Selvam M; Wang E; McWeeney SK; Tyner JW; Stölzel F; Mann M; Jayavelu AK; Khandanpour C
Blood; 2023 Dec; 142(25):2175-2191. PubMed ID: 37756525
[TBL] [Abstract][Full Text] [Related]
7. Presence of the
Vorwerk J; Sun K; Frank D; Neumann F; Hüve J; Budde PM; Liu L; Xie X; Patnana PK; Ahmed HMM; Opalka B; Lenz G; Jayavelu AK; Khandanpour C
Front Oncol; 2022; 12():903691. PubMed ID: 36003783
[TBL] [Abstract][Full Text] [Related]
8. Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications.
Möröy T; Khandanpour C
Front Oncol; 2019; 9():824. PubMed ID: 31508375
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
10. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
Li S; Fan R; Zhao XL; Wang XQ
Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
[TBL] [Abstract][Full Text] [Related]
12. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
13. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
15. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Gotoh N; Minato Y; Saitoh T; Takahashi N; Kasamatsu T; Souma K; Oda T; Hoshino T; Sakura T; Ishizaki T; Shimizu H; Takizawa M; Yokohama A; Tsukamoto N; Handa H; Murakami H
Eur J Haematol; 2020 Jun; 104(6):526-537. PubMed ID: 32003046
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
17. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
19. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
20. CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome.
Huh HJ; Chae SL; Lee M; Hong KS; Mun YC; Seong CM; Chung WS; Huh JW
Int J Lab Hematol; 2009 Jun; 31(3):344-51. PubMed ID: 18371060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
